How many insider trades does FilingIQ track for RPRX?

FilingIQ tracks 489 Form 4 insider transactions for RPRX (Royalty Pharma plc), covering filings from Dec 12, 2002 onwards. 17 of those were filed in the last 90 days.

Are RPRX insiders net buyers or net sellers?

Across the full Form 4 history for RPRX, 27 transactions (6%) were open-market purchases and 244 (50%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does RPRX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is RPRX in?

Royalty Pharma plc (RPRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $26.30B.

RPRX insider trading

NasdaqGS Healthcare

Royalty Pharma plc — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

489

Last 90 days

Buys / sells

6% / 50%

Market cap

$26.30B

About Royalty Pharma plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Company website: www.royaltypharma.com

RPRX insider activity at a glance

FilingIQ has scored 489 insider transactions for RPRX since Dec 12, 2002. The most recent filing in our index is dated May 6, 2026.

Across the full history, 27 open-market purchases and 244 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on RPRX insider trades is 60.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live RPRX trades on FilingIQ Raw filings on SEC EDGAR

Latest RPRX Form 4 filings

Lloyd George W. EVP, Investments & CLO

S Jun 2, 2023

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for RPRX?: FilingIQ tracks 489 Form 4 insider transactions for RPRX (Royalty Pharma plc), covering filings from Dec 12, 2002 onwards. 17 of those were filed in the last 90 days.
Are RPRX insiders net buyers or net sellers?: Across the full Form 4 history for RPRX, 27 transactions (6%) were open-market purchases and 244 (50%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does RPRX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is RPRX in?: Royalty Pharma plc (RPRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $26.30B.

Methodology & sources

Every RPRX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.